ANTX
AN2 Therapeutics, Inc. NASDAQ Listed Mar 25, 2022$4.63
Mkt Cap $126.9M
52w Low $1.00
61.4% of range
52w High $6.91
50d MA $3.63
200d MA $1.78
P/E (TTM)
-4.0x
EV/EBITDA
-0.4x
P/B
2.7x
Debt/Equity
0.0x
ROE
-66.3%
P/FCF
-1.2x
RSI (14)
—
ATR (14)
—
Beta
-1.32
50d MA
$3.63
200d MA
$1.78
Avg Volume
1.4M
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
1800 El Camino Real · Menlo Park, CA 94027 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.24 | -0.29 | -20.8% | 5.00 | -3.0% | -7.6% | -15.4% | +2.3% | -4.2% | -1.6% | — |
| Nov 12, 2025 | AMC | -0.23 | -0.31 | -34.8% | 1.18 | -5.9% | -4.2% | +0.9% | -1.8% | +0.0% | -3.6% | — |
| Aug 12, 2025 | AMC | -0.31 | -0.21 | +32.3% | 1.05 | +1.0% | +0.0% | +1.0% | +0.9% | +4.7% | +2.7% | — |
| May 13, 2025 | AMC | -0.26 | -0.35 | -34.6% | 1.18 | -1.7% | +0.8% | +3.4% | -1.6% | -1.7% | +0.0% | — |
| Mar 25, 2025 | AMC | -0.25 | -0.25 | +0.0% | 1.50 | -0.7% | +1.3% | -5.3% | -3.5% | -2.2% | +1.5% | — |
| Nov 13, 2024 | AMC | -0.37 | -0.43 | -16.2% | 1.01 | +2.0% | -1.0% | +0.0% | +0.0% | +6.0% | +22.6% | — |
| Aug 13, 2024 | AMC | -0.63 | -0.48 | +23.8% | 1.09 | -1.8% | -3.7% | -2.9% | -3.9% | +7.1% | +0.0% | — |
| May 14, 2024 | AMC | -0.61 | -0.56 | +8.2% | 2.31 | +1.3% | -1.7% | +0.0% | +0.0% | -1.8% | -2.7% | — |
| Mar 28, 2024 | AMC | -0.71 | -0.57 | +19.7% | 3.25 | +4.9% | +15.7% | -9.6% | -0.9% | -3.6% | -7.4% | — |
| Nov 9, 2023 | AMC | -0.63 | -0.65 | -3.2% | 15.40 | +0.9% | -7.1% | +4.8% | +6.3% | +0.8% | +2.3% | — |
| Aug 10, 2023 | AMC | -0.85 | -0.81 | +4.7% | 8.40 | -2.1% | +0.4% | +0.1% | +2.4% | +7.1% | +12.4% | — |
| May 11, 2023 | AMC | -0.68 | -0.79 | -16.2% | 5.06 | +2.0% | +0.6% | +7.1% | +36.0% | +11.7% | -5.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.22 | $1.24 | +1.6% | -1.6% | -4.2% | +7.8% | -1.6% | -1.6% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $1.50 | $1.49 | -0.7% | +1.3% | -5.3% | -3.5% | -2.2% | +1.5% |
| Feb 25 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $1.14 | $1.13 | -0.9% | -2.6% | +1.8% | -1.8% | +2.7% | -1.8% |
| Feb 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.14 | $1.11 | -2.6% | -4.4% | +1.8% | +5.4% | -6.0% | -1.8% |
| Nov 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.00 | $1.03 | +3.0% | +6.0% | +22.6% | -5.4% | +8.9% | +3.7% |
| Nov 18 | TD Cowen | Downgrade | Buy → Hold | — | $1.00 | $1.00 | +0.0% | +0.0% | +6.0% | +22.6% | -5.4% | +8.9% |
| Aug 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.64 | $1.58 | -40.2% | -61.0% | +0.0% | +5.8% | -3.7% | -2.9% |
| Jul 3 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $2.13 | $2.20 | +3.3% | +27.2% | -3.0% | -4.9% | +2.0% | +2.0% |
| May 16 | Evercore ISI | Maintains | In Line → In Line | — | $2.27 | $2.30 | +1.3% | +0.0% | +0.0% | -1.8% | -2.7% | -2.3% |
| Apr 2 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $3.76 | $3.76 | +0.0% | -9.6% | -0.9% | -3.6% | -7.4% | +0.0% |
| Apr 1 | Oppenheimer | Maintains | Perform → Perform | — | $3.25 | $3.41 | +4.9% | +15.7% | -9.6% | -0.9% | -3.6% | -7.4% |
| Feb 13 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $5.10 | $5.00 | -2.0% | -23.5% | -1.0% | -0.3% | -5.5% | +1.6% |
| Feb 12 | Evercore ISI | Downgrade | Outperform → In Line | — | $20.00 | $5.34 | -73.3% | -74.5% | -23.5% | -1.0% | -0.3% | -5.5% |
| Feb 12 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $20.00 | $5.34 | -73.3% | -74.5% | -23.5% | -1.0% | -0.3% | -5.5% |
| Feb 12 | Oppenheimer | Downgrade | Outperform → Perform | — | $20.00 | $5.34 | -73.3% | -74.5% | -23.5% | -1.0% | -0.3% | -5.5% |
| Mar 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.82 | $10.05 | +2.3% | -1.9% | +2.5% | +0.4% | -9.9% | +0.0% |
| Nov 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $14.87 | $15.00 | +0.9% | -1.0% | -0.1% | -3.3% | -2.9% | -5.7% |
| Apr 19 | Evercore ISI | Maintains | Outperform → Outperform | — | $14.79 | $14.61 | -1.2% | -5.3% | +0.1% | +4.8% | -0.7% | +2.9% |
| Apr 19 | Cowen & Co. | Maintains | Outperform → Outperform | — | $14.79 | $14.61 | -1.2% | -5.3% | +0.1% | +4.8% | -0.7% | +2.9% |
| Apr 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.79 | $14.61 | -1.2% | -5.3% | +0.1% | +4.8% | -0.7% | +2.9% |
No insider trades available.
8-K
Unknown — 8-K Filing
ANTX established an at-the-market offering agreement with Jefferies, allowing flexible capital raises without shareholder approval, which could dilute existing shareholders but provides crucial funding flexibility.
Apr 9
8-K
Unknown — 8-K Filing
ANTX repriced underwater stock options with extended terms, allowing management retention without new dilution, which signals confidence but may disappoint shareholders unhappy with existing dilution.
Mar 20
8-K
Unknown — 8-K Filing
ANTX's advancement of epetraborole into Phase 2 testing signals confidence in its boron platform's commercial potential, but investors should monitor clinical trial results closely as the company remains pre-revenue and capital-dependent.
Mar 17
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
ANTX issued equity to ITS TRANSFER AG, likely diluting existing shareholders but potentially bringing strategic partnership value or capital infusion needed for operations.
Mar 10
Data updated apr 24, 2026 6:15pm
· Source: massive.com